OBJECTIVE: To investigate the effect of pioglitazone on endothelial and adipose tissue dysfunction in newly detected IGT patients with CAD. METHODS AND DESIGN: Participants (n=25) were randomized to treatment with either placebo or pioglitazone (30 mg/day) for 12 weeks. Before and after treatment we evaluated endothelial function (flow-mediated dilation--FMD--of the brachial artery), circulating adipose and inflammatory markers (adiponectin isoforms, TNF-alpha, and high sensitivity-CRP), and insulin sensitivity (euglycemic hyperinsulinemic clamp). RESULTS: No significant changes were observed in subjects (n=12) treated with placebo. By contrast, subjects (n=13) treated with pioglitazone had significant improvement in FMD (10.8±5.3 vs 13.3±3.6%, p<0.01), accompanied by increased high molecular weight adiponectin (HMW-Ad) (1.7±1.2 vs 4.8±3.6 μg/ml, p<0.05) and decreased TNF-alpha (4.3±1.9 vs 3.2±1.2 pg/ml, p<0.05) associated to an increased glucose disposal (4.8±1.9 vs 5.4±2.0 mg kg(-1) min(-1), p<0.05). A multiple regression analysis indicated that increasing of HMW-Ad after pioglitazone predicted increased FMD. CONCLUSION: Pioglitazone significantly improves endothelial and adipose tissue dysfunction in pre-diabetic patients with CAD.

Rizza, S., Cardellini, M., Porzio, O., Pecchioli, C., Savo, A., Cardolini, I., et al. (2011). Pioglitazone improves endothelial and adipose tissue dysfunction in pre-diabetic CAD subjects. ATHEROSCLEROSIS, 215(1), 180-183 [10.1016/j.atherosclerosis.2010.12.021].

Pioglitazone improves endothelial and adipose tissue dysfunction in pre-diabetic CAD subjects

RIZZA, STEFANO;CARDELLINI, MARINA;PORZIO, OTTAVIA;LAURO, DAVIDE;SBRACCIA, PAOLO;LAURO, RENATO;FEDERICI, MASSIMO
2011-03-01

Abstract

OBJECTIVE: To investigate the effect of pioglitazone on endothelial and adipose tissue dysfunction in newly detected IGT patients with CAD. METHODS AND DESIGN: Participants (n=25) were randomized to treatment with either placebo or pioglitazone (30 mg/day) for 12 weeks. Before and after treatment we evaluated endothelial function (flow-mediated dilation--FMD--of the brachial artery), circulating adipose and inflammatory markers (adiponectin isoforms, TNF-alpha, and high sensitivity-CRP), and insulin sensitivity (euglycemic hyperinsulinemic clamp). RESULTS: No significant changes were observed in subjects (n=12) treated with placebo. By contrast, subjects (n=13) treated with pioglitazone had significant improvement in FMD (10.8±5.3 vs 13.3±3.6%, p<0.01), accompanied by increased high molecular weight adiponectin (HMW-Ad) (1.7±1.2 vs 4.8±3.6 μg/ml, p<0.05) and decreased TNF-alpha (4.3±1.9 vs 3.2±1.2 pg/ml, p<0.05) associated to an increased glucose disposal (4.8±1.9 vs 5.4±2.0 mg kg(-1) min(-1), p<0.05). A multiple regression analysis indicated that increasing of HMW-Ad after pioglitazone predicted increased FMD. CONCLUSION: Pioglitazone significantly improves endothelial and adipose tissue dysfunction in pre-diabetic patients with CAD.
mar-2011
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/09 - MEDICINA INTERNA
Settore MED/49 - SCIENZE TECNICHE DIETETICHE APPLICATE
English
Con Impact Factor ISI
Hypoglycemic Agents; Humans; Thiazolidinediones; Prediabetic State; Middle Aged; Adiponectin; Adipose Tissue; Male; Female; Endothelium, Vascular
Rizza, S., Cardellini, M., Porzio, O., Pecchioli, C., Savo, A., Cardolini, I., et al. (2011). Pioglitazone improves endothelial and adipose tissue dysfunction in pre-diabetic CAD subjects. ATHEROSCLEROSIS, 215(1), 180-183 [10.1016/j.atherosclerosis.2010.12.021].
Rizza, S; Cardellini, M; Porzio, O; Pecchioli, C; Savo, A; Cardolini, I; Senese, N; Lauro, D; Sbraccia, P; Lauro, R; Federici, M
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
pio_CAD.pdf

solo utenti autorizzati

Descrizione: articolo principale
Licenza: Copyright dell'editore
Dimensione 173.03 kB
Formato Adobe PDF
173.03 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/52440
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 28
social impact